Idiotypic Suppression of B-Cell-Derived Tumors

Models for Lymphocyte Regulation
  • Abul K. Abbas
  • Gina Moser


The expression of idiotypic determinants on immunoglobulin-producing monoclonal neoplasms has been recognized for over a decade. Tumor idiotypes have two major applications: they are surface determinants against which highly specific immunity can be induced and used for therapy, and they are targets for immunoregulatory cells and antibodies, so that the tumors can serve as models for the regulation of nonneoplastic lymphocytes. Since the first demonstration of idiotype-specific tumor immunity against murine myelomas,1 the general validity of this approach has been convincingly established by numerous investigators. It is now clear that anti-idiotypic antibodies and/or T lymphocytes can suppress the growth or mediate the rejection of murine and human B-cell lymphomas and leukemias,(2,3) a variety of antibody-secreting myelomas,(4,5) and “hybridomas” produced by fusion of immune B lymphocytes and drug-marked myelomas.(6) The clinical applicability of such approaches is limited by the problem of producing specific anti-idiotypic antibodies and effector T lymphocytes against individual neoplasms. However, modern advances in techniques for long-term cell culture and somatic cell hybridization may well make it feasible to direct immunotherapeutic regimens against the idiotypic determinants present on B-cell-derived neoplasms.


Myeloma Cell Accessory Cell Myeloma Protein Immunoregulatory Cell Delay Hypersensitivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S., and Eisen, H. N., 1972, Myeloma proteins as tumor-specific transplantation antigens, Proc. Natl. Acad. Sci. USA 69:1540–1545.PubMedCrossRefGoogle Scholar
  2. 2.
    Vitetta, E. S., Krolick, K. A., and Uhr, J. W., 1982, Neoplastic B cells as targets for antibody-ricin A chain immunotoxins, Immunol. Rev. 62:159–183.PubMedCrossRefGoogle Scholar
  3. 3.
    Miller, R. A., Maloney, D. G., Warnke, R., and Levy, R., 1982, Treatment of B-cell lymphoma with monoclonal anti-idiotypic antibody, N. Engl. J. Med. 306:517–522.PubMedCrossRefGoogle Scholar
  4. 4.
    Beatty, P. G., Kim, B. S., Rowley, D. A., and Coppelson, L. W., 1976, Antibody against the antigen receptor of a plasmacytoma prolongs survival of mice bearing the tumor, J. Immunol. 116:1391–1396.PubMedGoogle Scholar
  5. 5.
    Flood, P. M., Phillipps, C., Taupier, M. A., and Schreiber, H., 1980, Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes, J. Immunol. 124:424–430.PubMedGoogle Scholar
  6. 6.
    Kresina, T. F., Baine, Y., and Nisonoff, A., 1983, Adoptive transfer of resistance to growth of an idiotypesecreting hybridoma by T cells from idiotypically suppressed mice, J. Immunol. 130:1478–1482.PubMedGoogle Scholar
  7. 7.
    Abbas, A. K., 1982, Immunologic regulation of lymphoid tumor cells: Model systems for lymphocyte function, Adv. Immunol. 32:301–368.PubMedCrossRefGoogle Scholar
  8. 8.
    Sato, G. H., and Ross, R. (eds.), 1979, Hormones and Cell Culture, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.Google Scholar
  9. 9.
    Abbas, A. K., and Klaus, G. G. B., 1977, Inhibition of antibody production in plasmacytoma cells by antigen, Eur. J. Immunol. 7:667–674.PubMedCrossRefGoogle Scholar
  10. 10.
    Abbas, A. K., and Klaus, G. G. B., 1978, Antigen-antibody complexes suppress antibody production by mouse plasmacytoma cells in vitro, Eur. J. Immunol. 8:217–220.PubMedCrossRefGoogle Scholar
  11. 11.
    Boyd, A. W., and Schrader, J. W., 1980, Mechanisms of effector-cell blockade. I. Antigen-induced suppression of Ig synthesis in a hybridoma cell line, and correlation with cell-associated antigen, J. Exp. Med. 151:1436–1451.PubMedCrossRefGoogle Scholar
  12. 12.
    Abbas, A. K., 1979, Antigen and T lymphocyte mediated suppression of myeloma cells: Model systems for regulation of lymphocyte function, Immunol. Rev. 48:245–264.PubMedCrossRefGoogle Scholar
  13. 13.
    Lynch, R. G., Rohrer, J. W., Odermatt, B., Gebel, H. M., Autry, J. M., and Hoover, R. G., 1979, Immunoregulation of murine myeloma cell growth and differentiation: A monoclonal model of B cell differentiation, Immunol. Rev. 48:45–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Battisto, J. R., and Bloom, B. R., 1966, Dual immunological unresponsiveness induced by cell membranecoupled hapten or antigen, Nature 212:156–158.PubMedCrossRefGoogle Scholar
  15. 15.
    Abbas, A. K., Perry, L. L., Bach, B. A., and Greene, M. I., 1980, Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants, J. Immunol. 124:1160–1166.PubMedGoogle Scholar
  16. 16.
    Germain, R. N., and Benacerraf, B., 1981, A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression, Scand. J. Immunol. 13:1–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Sy, M.-S., Nisonoff, A., Germain, R. N., Benacerraf, B., and Greene, M. I., 1981, Antigen- and receptordriven regulatory mechanisms. VIII. Suppression of idiotype-negative p-azobenzenearsonate-specific T cells results from the intereaction of an anti-idiotypic second-order T suppressor cell with a cross-reactive idiotype-positive p-azobenzenearsonate primed T cell target, J. Exp. Med. 153:1415–1425.PubMedCrossRefGoogle Scholar
  18. 18.
    Abbas, A. K., Takaoki, M., and Greene, M. I., 1982, T lymphocyte-mediated suppression of myeloma function in vitro. IV. Generation of effector suppressor cells specific for myeloma idiotypes, J. Exp. Med. 155:1216–1221.PubMedCrossRefGoogle Scholar
  19. 19.
    Milburn, G. L., and Lynch, R. G., 1982, Immunoregulation of murine myeloma in vitro. II. Suppression of MOPC-315 immunoglobulin secretion and synthesis by idiotype-specific suppressor T cells, J. Exp. Med. 155:852–862.PubMedCrossRefGoogle Scholar
  20. 20.
    Abbas, A. K., Burakoff, S. J., Gefter, M. L., and Greene, M. I., 1980, T lymphocyte-mediated suppression of myeloma function in vitro. III. Regulation of antibody production in hybrid myeloma cells by T lymphocytes, J. Exp. Med. 152:969–978.PubMedCrossRefGoogle Scholar
  21. 21.
    Moser, G., Tominaga, A., Greene, M. I., and Abbas, A. K., 1983, Accessory cells in immune suppression. I. Role of I-A-positive accessory cells in effector phase idiotype-specific suppression of myeloma function, J. Immunol. 131:1728–1733.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Abul K. Abbas
    • 1
  • Gina Moser
    • 1
  1. 1.Departments of PathologyHarvard Medical School and Brigham and Women’s HospitalBostonUSA

Personalised recommendations